In the combination therapy groups, there was a notable increase in CD8+ T-cells exhibiting a tumor-reactive CD39+CD103+ phenotype (PBS VS α4-1BB/AlloDC P=0.0127) (Figure 3J). This evidence concerns the gene CD8A and neoplasm.